A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Completed · Phase 1

Conditions studied: Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm

In brief

This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits.

Key facts

Study ID
NCT00001444
Run by
National Cancer Institute (NCI)
People needed
51
Starts
1995-08-01
Expected to finish
2002-05-01
Last updated by the study team
2008-03-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.